The infant was admitted to our department having experienced increased leucorrhea for 1 month; she had no other medical history. Both her breasts were enlarged (Tanner stage B2) with no pain. Ultrasound analysis revealed a hypoechoic solid mass measuring 6.5 cm×5.0 cm× 5.0 cm in the left adnexal area. The size of her uterus was age-appropriate, with an endometrial thickness of 1 mm. No free pelvic fluid was detected. Levels of tumor markers including CA125, CA19-9, AFP and CEA were normal. Analysis of sex hormone levels showed the following: estradiol, 76.2 pg/ml; FSH, less than 0.1 U/L; LH, less than 0.1 U/L; testosterone, 0.7 ng/ml; and PRL, 4.5 ng/ml. Exploratory laparotomy was performed after intestinal preparation and induction of general anesthesia. An ovarian mass measuring 6.0 cm×6.0 cm× 5.0 cm was detected on the left side, and left ovary resection was performed ( Figure 1A ). The right ovary was measured to be 2.0 cm×1.0 cm×1.0 cm and showed normal morphology. Pelvic lymph nodes were normal. Pelvic washing fluid was negative for tumor cells, consistent with a stage IA ovarian tumor. Histopathology definitively showed an ovarian JGCT ( Figure  1B , C). Immunohistology showed positive staining for inhibin A, calretinin, Muc-5, CD56, CD99 and Cripto-1 ( Figure 1D ). The patient recovered well after the operation, and no chemotherapy or radiation was administered. At 10 months after surgery, she remained tumor-free and showed normal results by ultrasound imaging and sex hormone analysis.
JGCT is a rare gynecologic neoplasm, encountered predominantly in young women with a mean age of 13 years. 1 Tumors rarely occur in children younger than 2 years. A review in 1997 identified only 36 cases of JGCT in patients younger than 2 years old, with 21 of these patients younger than 1 year. 2 Most JGCT patients present with isosexual precocious pseudopuberty involving breast enlargement, pubic hair development, increased vaginal secretions or bleeding. 1 Analysis of serum hormone levels may reveal an elevated estradiol concentration. Patients with JGCT may also present with non-specific signs and symptoms such as pain, abdominal bloating and a palpable mass in the lower abdomen. 2 The principal signs and symptoms in our patient were breast enlargement and increased vaginal secretions. However, imaging tests are usually not specific enough to differentiate JGCT from other ovarian tumors. When imaging reveals a solid mass in the pelvic region, histopathology should be performed to confirm a diagnosis of JGCT according to the following criteria: a diffuse or macrofollicular pattern, rare Call-Exner bodies, abundant luteinization of either the granulosa or theta cell elements or both, hyperchromatic nuclei, abundant mitotic figures, and nuclear atypia. 2 In particular, the absence of Call-Exner bodies and abundant luteinization helps differentiate JGCTs from adult granulosa cell tumors (AGCTs), which usually occur in adults older than 30. Patients with AGCT usually show abundant Call-Exner bodies and rare luteinization. Histopathology of our patient was consistent with all JGCT criteria, and we further supported the diagnosis using imunohistochemistry to show the presence of inhibin A, calretinin and CD99.
The tumor in our patient was detected at stage IA, and no further chemotherapy or radiation was administered. Since most JGCTs in infants are unilateral in stage I, unilateral oophorectomy can be an effective treatment, with no need for biopsy on the other side. The patient was healthy at 10 months of follow-up and her prognosis is good; further follow-up will be conducted annually. 
